抗血管内皮生长因子治疗角膜新生血管的研究进展

发布时间：2018-04-28 19:34

本文选题：抗血管内皮生长因子 + 角膜新生血管　；参考：《眼科新进展》2014年07期

【摘要】：角膜新生血管可能会导致视力严重减退,主要与其阻碍光线导致了角膜瘢痕、引起角膜的炎症反应和水肿进而损害损害视力有关。角膜的无血管状态是一个积极主动的过程,角膜能够维持透明性是由于血管生长因子和抗血管生长因子的精确平衡。血管内皮生长因子(vascular endothelial growth factor,VEGF)是最重要的调控介质之一,其上调可以诱发血管生成。而抗VEGF治疗对于许多疾病有效,如年龄相关性黄斑变性、糖尿病视网膜病变等血管生成疾病,同样它们对于角膜新生血管的治疗也具有巨大的潜力,本文就角膜新生血管的抗VEGF治疗现状进行了综述。
[Abstract]:Corneal neovascularization may lead to severe loss of visual acuity, which is mainly related to the obstruction of light, which leads to corneal scar, inflammation and edema of cornea, and damages visual acuity. Corneal avascular state is a proactive process, and corneal transparency is due to the accurate balance of vascular growth factor and anti-vascular growth factor. Vascular endothelial growth factor (VEGF) is one of the most important regulatory mediators, and its up-regulation can induce angiogenesis. Anti- VEGF therapy is effective for many diseases, such as age-related macular degeneration, diabetic retinopathy and other angiogenic diseases, and they also have great potential for corneal neovascularization. This article reviews the current status of anti-VEGF therapy for corneal neovascularization.
【作者单位】：哈尔滨医科大学附属第一医院眼科;
【基金】：国家自然科学基金资助(编号:81201184)~~
【分类号】：R772.2

【参考文献】